Definiens scooped up by AstraZeneca
This article was originally published in Clinica
Executive Summary
Image analysis and tumor biomarker specialist Definiens is being bought AstraZeneca as it consolidates its position in oncology R&D. AstraZeneca's MedImmune unit will acquire 100% of Definiens' shares for $150m upfront and make additional predetermined milestone payments.
You may also be interested in...
Wellington Partners Maintains Medtech Interests With New €210M Eurocentric Fund WPLS-V
While other venture capitalists are curbing their efforts in medtech, Wellington Partners intends to maintain its support for the sector earmarking about half of its new €210m WPLS-V fund for European medtech opportunities.
Wellington Partners Unveils €210m Eurocentric Biotech/Medtech Fund WPLS-V
With its WPLS-IV fund now fully committed, Wellington Partners has returned to the market and raised €210m in its WPLS-V fund which will focus on European biotech and medtech opportunities.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.